EA033403B1 - Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения - Google Patents

Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения

Info

Publication number
EA033403B1
EA033403B1 EA201690377A EA201690377A EA033403B1 EA 033403 B1 EA033403 B1 EA 033403B1 EA 201690377 A EA201690377 A EA 201690377A EA 201690377 A EA201690377 A EA 201690377A EA 033403 B1 EA033403 B1 EA 033403B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pai
antibodies
activator inhibitor
plasminogen
ways
Prior art date
Application number
EA201690377A
Other languages
English (en)
Russian (ru)
Other versions
EA201690377A1 (ru
Inventor
Alla Pritsker
Patrick Grailhe
Alexey Rak
Magali Mathieu
Christopher Ryan Morgan
Nicolas Baurin
Bruno Poirer
Cyril Daveu
Francis Duffieux
Han Li
Dorothea KOMINOS
Philip Janiak
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Priority claimed from PCT/US2014/050896 external-priority patent/WO2015023752A1/en
Publication of EA201690377A1 publication Critical patent/EA201690377A1/ru
Publication of EA033403B1 publication Critical patent/EA033403B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
EA201690377A 2013-08-13 2014-08-13 Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения EA033403B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361865451P 2013-08-13 2013-08-13
EP14305757 2014-05-22
PCT/US2014/050896 WO2015023752A1 (en) 2013-08-13 2014-08-13 Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof

Publications (2)

Publication Number Publication Date
EA201690377A1 EA201690377A1 (ru) 2016-06-30
EA033403B1 true EA033403B1 (ru) 2019-10-31

Family

ID=56194112

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690377A EA033403B1 (ru) 2013-08-13 2014-08-13 Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения

Country Status (17)

Country Link
US (4) US9845363B2 (cg-RX-API-DMAC7.html)
JP (5) JP6696899B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160035077A (cg-RX-API-DMAC7.html)
CN (2) CN105705520B (cg-RX-API-DMAC7.html)
BR (1) BR112016002753A2 (cg-RX-API-DMAC7.html)
CL (1) CL2016000324A1 (cg-RX-API-DMAC7.html)
CR (2) CR20190319A (cg-RX-API-DMAC7.html)
DO (1) DOP2016000042A (cg-RX-API-DMAC7.html)
EA (1) EA033403B1 (cg-RX-API-DMAC7.html)
ES (1) ES2770507T3 (cg-RX-API-DMAC7.html)
HK (1) HK1221725A1 (cg-RX-API-DMAC7.html)
MX (2) MX2016001851A (cg-RX-API-DMAC7.html)
PE (1) PE20160244A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016500239A1 (cg-RX-API-DMAC7.html)
SG (1) SG10201710013RA (cg-RX-API-DMAC7.html)
TN (1) TN2016000048A1 (cg-RX-API-DMAC7.html)
UA (1) UA118267C2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201710013RA (en) * 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
CA3008694C (en) 2015-12-18 2022-11-29 Talengen International Limited Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
CN108778320A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
ES3046932T3 (en) 2015-12-18 2025-12-02 Talengen Int Ltd Plasminogen preventing or treating diabetic retinopathy
CN108210897A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肺纤维化的药物及其用途
WO2018107695A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肾纤维化的方法
JP7175270B2 (ja) * 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
CN108210904A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 治疗动脉粥样硬化及其并发症的药物及其用途
EP3556380A4 (en) * 2016-12-15 2020-05-13 Talengen International Limited METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
JP7214225B2 (ja) 2016-12-15 2023-01-30 タレンゲン インターナショナル リミテッド 脂肪肝を予防および治療するための方法
JP7335609B2 (ja) 2017-06-19 2023-08-30 タレンゲン インターナショナル リミテッド Ｇｌｐ－１／ｇｌｐ－１ｒを調節制御する方法および薬剤
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
KR102733407B1 (ko) * 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
KR20210110848A (ko) 2018-12-28 2021-09-09 카탈리스트 바이오사이언시즈, 인코포레이티드 변형된 유로키나제 유형 플라스미노겐 활성제 폴리펩타이드 및 사용 방법
WO2021066062A1 (ja) 2019-09-30 2021-04-08 株式会社レナサイエンス 免疫チェックポイント分子の発現抑制剤
KR20220093327A (ko) * 2019-10-28 2022-07-05 모나쉬 유니버시티 플라스미노겐에 결합하기 위한 항체
IL293195A (en) * 2019-12-05 2022-07-01 Seagen Inc Anti-avb6 antibodies and antibody-drug conjugates
CN115605219A (zh) * 2020-02-11 2023-01-13 泰伦基国际有限公司（Hk） 一种治疗病毒性肺炎的方法和药物
CN111072780B (zh) * 2020-03-24 2020-06-23 深圳汉盛汇融再生医学科技有限公司 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用
BR112022019131A2 (pt) * 2020-05-21 2022-11-29 Zydus Lifesciences Ltd Variante fc e composiçâo
CN114605550B (zh) * 2020-12-08 2023-09-22 东莞市朋志生物科技有限公司 抗ca19-9的抗体、其应用和检测ca19-9的试剂盒
CN114686441B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 一种能分泌tPAI-C单克隆抗体的杂交瘤细胞株及其应用
CN114686442B (zh) * 2020-12-31 2023-11-07 广州万孚生物技术股份有限公司 一种杂交瘤细胞株及其应用
CN115873120B (zh) * 2022-09-08 2025-10-21 厦门英博迈生物科技有限公司 一种纤溶酶α2纤溶酶抑制物复合物抗体及应用
WO2025032553A1 (en) * 2023-08-10 2025-02-13 Cochlear Limited Methods of treating inner ear fibrosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090136500A1 (en) * 2007-09-07 2009-05-28 Cisthera Incorporated Humanized PAI-1 Antibodies
WO2011139973A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5422245A (en) * 1985-07-12 1995-06-06 Fonden Til Fremme Af Eksperimental Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for assay of the inhibitors
DK319685A (da) * 1985-07-12 1987-01-13 Fonden Til Fremme Af Eksperime Monoklonale antistoffer, fremgangsmaade til frembringelse af antistofferne, hybridomaceller, der producerer antistofferne, og anvendelse af antistofferne
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
JP2750732B2 (ja) * 1988-04-04 1998-05-13 帝人株式会社 ヒトプラスミノーゲンアクティベーターインヒビター・１−ヒト組織プラスミノーゲンアクティベーター複合体の免疫学的測定方法
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
JPH1014592A (ja) * 1996-07-04 1998-01-20 Tanabe Seiyaku Co Ltd ラットｐａｉ−１に対するモノクローナル抗体
ATE386809T1 (de) 1996-08-02 2008-03-15 Bristol Myers Squibb Co Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2001229441A1 (en) * 2000-01-14 2001-07-24 Tanox, Inc. Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
AU2002216847A1 (en) 2000-10-26 2002-05-06 K.U. Leuven Research And Development Epitopes of pai-1
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CA2476761A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN1668312A (zh) * 2002-05-13 2005-09-14 洛杉矶儿童医院 疤痕疙瘩和其它的皮肤或内部的创伤或损伤中异常疤痕形成的处理和抑制
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
PL1706424T3 (pl) 2004-01-12 2010-04-30 Mentrik Biotech Llc Warianty regionu Fc
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CA2565961A1 (en) 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US20090202524A1 (en) 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
UA117446C2 (uk) 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
US7771720B2 (en) 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
US20100254979A1 (en) * 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof
SG10201710013RA (en) * 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090136500A1 (en) * 2007-09-07 2009-05-28 Cisthera Incorporated Humanized PAI-1 Antibodies
WO2011139973A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
C N BERRY, C LUNVEN, I LECHAIRE, C GIRARDOT, S E O'CONNOR: "Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis", BRITISH JOURNAL OF PHARMACOLOGY, NATURE PUB. GROUP, ETC., vol. 125, no. 1, 1 September 1998 (1998-09-01), pages 29 - 34, XP055082632, ISSN: 00071188, DOI: 10.1038/sj.bjp.0702030 *
DEBROCK, S. DECLERCK, P.J.: "Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms", BIOCHIMICA ET BIOPHYSICA ACTA. PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, ELSEVIER, AMSTERDAM; NL, vol. 1337, no. 2, 8 February 1997 (1997-02-08), AMSTERDAM; NL, pages 257 - 266, XP004281570, ISSN: 0167-4838, DOI: 10.1016/S0167-4838(96)00173-2 *
DOMINIK NAESSENS, ANN GILS, GRIET COMPERNOLLE, PAUL DECLERCK: "Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition.", THROMBOSIS AND HAEMOSTASIS, vol. 90, no. 1, 1 July 2003 (2003-07-01), pages 52 - 58, XP055082583, ISSN: 03406245, DOI: 10.1267/THRO03010052 *
I. VERHAMME, KVASSMAN, DAY, DEBROCK, VLEUGELS, DECLERCK, SHORE: "Accelerated Conversion of Human Plasminogen Activator Inhibitor-1 to Its Latent Form by Antibody Binding", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 274, no. 25, 18 June 1999 (1999-06-18), pages 17511 - 17517, XP055082621, ISSN: 00219258, DOI: 10.1074/jbc.274.25.17511 *
K. VERBEKE, A. GILS, P. J. DECLERCK: "Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI-1 inhibitor", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUB., C2003-, vol. 2, no. 2, 1 February 2004 (2004-02-01), pages 289 - 297, XP055082582, ISSN: 15387933, DOI: 10.1111/j.1538-7933.2004.00582.x *
K. VERBEKE, A. GILS, P. J. DECLERCK: "Inhibition of plasminogen activator inhibitor-1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUB., C2003-, vol. 2, no. 2, 1 February 2004 (2004-02-01), pages 298 - 305, XP055082581, ISSN: 15387933, DOI: 10.1111/j.1538-7933.2004.00583.x *
KOEN VERBEKE, ANN GILS, JEAN-MARIE STASSEN, PAUL DECLERCK: "Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative.", THROMBOSIS AND HAEMOSTASIS, vol. 89, no. 1, 1 January 2003 (2003-01-01), pages 74 - 82, XP055082626, ISSN: 03406245, DOI: 10.1267/THRO03010074 *
N. V. GORLATOVA, HASSAN ELOKDAH, KRISTI FAN, DAVID CRANDALL, DANIEL LAWRENCE: "Mapping of a Conformational Epitope on Plasminogen Activator Inhibitor-1 by Random Mutagenesis. IMPLICATIONS FOR SERPIN FUNCTION", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 278, no. 18, 25 April 2003 (2003-04-25), pages 16329 - 16335, XP055082586, ISSN: 00219258, DOI: 10.1074/jbc.M208420200 *
NOVOA DE ARMAS, H. DEWILDE, M. VERBEKE, K. DE MAEYER, M. DECLERCK, P.J.: "Study of Recombinant Antibody Fragments and PAI-1 Complexes Combining Protein-Protein Docking and Results from Site-Directed Mutagenesis", STRUCTURE, ELSEVIER, AMSTERDAM, NL, vol. 15, no. 9, 7 September 2007 (2007-09-07), AMSTERDAM, NL, pages 1105 - 1116, XP022234543, ISSN: 0969-2126, DOI: 10.1016/j.str.2007.07.009 *
TROELS WIND, MADS A. JENSEN AND PETER A. ANDREASEN: "Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1 : Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding", EUROPEAN JOURNAL OF BIOCHEMISTRY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 268, no. 4, 1 February 2001 (2001-02-01), GB, pages 1095 - 1106, XP008164019, ISSN: 0014-2956, DOI: 10.1046/j.1432-1327.2001.2680041095.x *

Also Published As

Publication number Publication date
JP2016529255A (ja) 2016-09-23
SG10201710013RA (en) 2018-01-30
US20230015181A1 (en) 2023-01-19
JP6907380B2 (ja) 2021-07-21
MX2016001851A (es) 2016-05-16
KR20160035077A (ko) 2016-03-30
PH12016500239A1 (en) 2016-05-16
TN2016000048A1 (en) 2017-07-05
HK1221725A1 (zh) 2017-06-09
US20160200831A1 (en) 2016-07-14
JP7568756B2 (ja) 2024-10-16
CN112142845A (zh) 2020-12-29
CN105705520B (zh) 2020-09-25
US20190359729A1 (en) 2019-11-28
JP2025011161A (ja) 2025-01-23
JP7764565B2 (ja) 2025-11-05
US9845363B2 (en) 2017-12-19
ES2770507T3 (es) 2020-07-01
US20180155444A1 (en) 2018-06-07
BR112016002753A2 (pt) 2017-11-21
CN105705520A (zh) 2016-06-22
DOP2016000042A (es) 2016-04-04
CR20160117A (es) 2016-05-20
JP7223069B2 (ja) 2023-02-15
EA201690377A1 (ru) 2016-06-30
MX2019008803A (es) 2019-09-16
JP2020125333A (ja) 2020-08-20
JP2021155440A (ja) 2021-10-07
CR20190319A (es) 2019-08-29
JP6696899B2 (ja) 2020-05-20
PE20160244A1 (es) 2016-05-10
UA118267C2 (uk) 2018-12-26
JP2023055852A (ja) 2023-04-18
CL2016000324A1 (es) 2016-10-21

Similar Documents

Publication Publication Date Title
EA033403B1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
JOP20200132A1 (ar) صيغة مجففة بالتبريد من جسم مضاد أحادي النسيلة ضد ترانس ثيرتين
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
EA201791773A1 (ru) Цистеиновая протеаза
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201890175A1 (ru) Антитела к cd40
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201790922A1 (ru) Ингибиторы бромодомена
EA201592203A1 (ru) Способы лечения таупатии
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
EA201690064A1 (ru) Антитела к лектин-подобному рецептору 1 окисленных ldl и способы применения
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU